Amicus Therapeutics IncNASDAQ:FOLD
- LAST PRICE10.3800
- TODAY'S CHANGE (%)-0.2700 (-2.5352%)
- Bid / Lots10.0100/ 5
- Ask / Lots11.3300/ 15
- Open / Previous Close10.6800 / 10.6500
- Day Range
- 52 Week Range
- Volume2,090,921
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FOLD |
|---|---|---|
| 02:24 ET | 389 | 10.45 |
| 02:26 ET | 1477 | 10.44 |
| 02:27 ET | 961 | 10.44 |
| 02:29 ET | 5902 | 10.435 |
| 02:31 ET | 2400 | 10.44 |
| 02:33 ET | 17701 | 10.44 |
| 02:36 ET | 1159 | 10.44 |
| 02:38 ET | 300 | 10.44 |
| 02:40 ET | 1706 | 10.43 |
| 02:42 ET | 5710 | 10.435 |
| 02:44 ET | 3218 | 10.435 |
| 02:45 ET | 6138 | 10.44 |
| 02:47 ET | 2206 | 10.445 |
| 02:49 ET | 600 | 10.45 |
| 02:51 ET | 4099 | 10.475 |
| 02:54 ET | 8366 | 10.465 |
| 02:56 ET | 1629 | 10.46 |
| 02:58 ET | 9673 | 10.46 |
| 03:00 ET | 200 | 10.46 |
| 03:02 ET | 5199 | 10.46 |
| 03:03 ET | 1591 | 10.46 |
| 03:05 ET | 7842 | 10.465 |
| 03:07 ET | 2737 | 10.4675 |
| 03:09 ET | 5924 | 10.455 |
| 03:12 ET | 4507 | 10.44 |
| 03:14 ET | 5030 | 10.44 |
| 03:16 ET | 3506 | 10.4475 |
| 03:18 ET | 3317 | 10.4475 |
| 03:20 ET | 15151 | 10.445 |
| 03:21 ET | 1200 | 10.4475 |
| 03:23 ET | 1500 | 10.44 |
| 03:25 ET | 34042 | 10.455 |
| 03:27 ET | 800 | 10.45 |
| 03:30 ET | 2722 | 10.46 |
| 03:32 ET | 12773 | 10.45 |
| 03:34 ET | 1331 | 10.44 |
| 03:36 ET | 7095 | 10.43 |
| 03:38 ET | 1088 | 10.435 |
| 03:39 ET | 1100 | 10.4325 |
| 03:41 ET | 10959 | 10.43 |
| 03:43 ET | 2573 | 10.42 |
| 03:45 ET | 4333 | 10.42 |
| 03:48 ET | 18235 | 10.42 |
| 03:50 ET | 6839 | 10.42 |
| 03:52 ET | 71656 | 10.395 |
| 03:54 ET | 16422 | 10.375 |
| 03:56 ET | 31664 | 10.395 |
| 03:57 ET | 14061 | 10.39 |
| 03:59 ET | 82789 | 10.38 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amicus Therapeutics Inc | 3.1B | -21.1x | --- |
Denali Therapeutics Inc | 3.3B | -22.2x | --- |
Genmab A/S | 17.7B | 22.9x | +22.71% |
MorphoSys AG | 2.8B | -5.4x | --- |
ADMA Biologics Inc | 3.1B | -654.9x | --- |
Beam Therapeutics Inc | 2.2B | -14.9x | --- |
Company Information
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
Contact Information
- Headquarters
- 3675 Market StreetPHILADELPHIA, PA, United States 19104
- Phone
- 215-921-7600
- Fax
- 609-662-2001
Executives
- Independent Chairman of the Board
- Michael Raab
- President, Chief Executive Officer, Director
- Bradley Campbell
- Chief Financial Officer
- Simon Harford
- Chief People Officer
- David Clark
- Chief Legal Office, General Counsel, Company Secretary
- Ellen Rosenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $423.5M |
Shares Outstanding | 296.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-0.49 |
Book Value | $0.55 |
P/E Ratio | -21.1x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
